Erratum to: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Diabetologia

• Publication date

  1996-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF00418542PMID 8781766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The fourth Musketeer — from Alexandre Dumas to Claude Bernard

  2006cited by this paper
• Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment

  2005cited by this paper
• Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

  1995cited by this paper
• Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

  1995cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

  1995cited by this paper
• Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study

  1994cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994influential reference
• Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome.

  1994cited by this paper
• Management of non-insulin-dependent diabetes mellitus.

  1994influential reference
• Effects of a New Oral Hypoglycaemic Agent (CS‐045) on Metabolic Abnormalities and Insulin Resistance in Type 2 Diabetes

  1994influential reference
• Pathogenesis of non-insulin-dependent diabetes mellitus.

  1994cited by this paper
• Troglitazone Prevents Glucose-Induced Insulin Resistance of Insulin Receptor in Rat-1 Fibroblasts

  1994cited by this paper
• Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen Study

  1994cited by this paper
• Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

  1992cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992influential reference
• Pathogenesis of NIDDM: A Balanced Overview

  1992cited by this paper
• Can Life‐styles of Subjects With Impaired Glucose Tolerance Be Changed? A Feasibility Study

  1992cited by this paper
• Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

  1991cited by this paper
• A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

  1991influential reference
• Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045.

  1991cited by this paper
• Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malmö feasibility study

  1991cited by this paper
• Oral hypoglycemic agents.

  1989influential reference
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988influential reference
• Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones.

  1988cited by this paper
• Pathogenesis of non-insulin dependent diabetes mellitus

  1988cited by this paper
• The design and analysis of clinical experiments

  1987cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes.

  1982cited by this paper
• Letter: Clonidine withdrawal and blockade.

  1976cited by this paper
• Radioimmunological determination of human C-peptide in serum

  1975influential reference
• Oral hypoglycaemic agents

  1973cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• PREVENTION OF DIABETES MELLITUS.

  1965cited by this paper
• Critical Variables in the Radioimmunoassay of Serum Insulin Using the Double Antibody Technic

  1965cited by this paper
• The Relation between the Minor Components of Whole Normal Human Adult Hemoglobin as Isolated by Chromatography and Starch Block Electrophoresis

  1961cited by this paper

• 2,4-Dioxochroman Moiety Linked to 1,2,3-triazole Derivatives as Novel α-glucosidase Inhibitors: Synthesis, In vitro Biological Evaluation, and Docking Study

  2020cites this paper
• Ferroptosis involves in renal tubular cell death in diabetic nephropathy.

  2020cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• Diabetes: the place of new therapies

  2018cites this paper
• Oral Antihyperglycemic Therapy for Type 2 Diabetes

  2017cites this paper
• Biological and Chemical Investigation of Panamanian Plants for Potential Utility against Metabolic Syndrome

  2016cites this paper
• Pharmacogenetics and Metabolic Disease

  2016cites this paper
• Hepatic Peroxisome Proliferator-Activated Receptor Gamma Signaling Contributes to Alcohol-Induced Hepatic Steatosis and Inflammation in Mice.

  2016cites this paper
• Anti-Diabetic Activity Of Aqueous Extract Of Pithecellobium Dulce Benth Fruit Peel On Streptozotocin Induced Diabetic Rats

  2016cites this paper
• Chronic consumption of an inositol-enriched beverage ameliorates endothelial dysfunction and oxidative stress in type 2 diabetes

  2015cites this paper
• The antidiabetic properties of four plants grown in India and KwaZulu-Natal, South Africa, suitable for diabetic management

  2015cites this paper
• Drug Information Rounds

  2015cites this paper
• The Synergistic Effects of Pioglitazone on the Glucose-Lowering Action of Metformin in Relation to OCT1 and Gluts m-RNA Expression in Healthy Volunteer

  2015cites this paper
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review

  2014cites this paper
• Assay Method for Quality Control and Stability Studies of a New Antidiabetic Agent (S-001-469)

  2014cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review

  2014cites this paper
• Modulation of the Transcriptional Activity of Peroxisome Proliferator-Activated Receptor Gamma by Protein-Protein Interactions and Post-Translational Modifications

  2013cites this paper
• Strategies for Better Diabetes Control in the US

  2012cites this paper
• Characterization of apoptosis resistance in human preadipocytes and adipocytes

  2012cites this paper
• Peroxisome Proliferator-Activated Receptor-γ

  2012cites this paper
• Controversies surrounding the clinical potential of cinnamon for the management of diabetes

  2012cites this paper
• Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice

  2012cites this paper
• Characterization of apoptosis resistance in human preadipocytes and adipocytes

  2012cites this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cites this paper
• A New Era in Diabetic Agents: Hope for Diabetics

  2012cites this paper
• Gene expression profiling in primary rat hepatocytes for the prediction of hepatotoxicity

  2012cites this paper
• Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

  2012influential citation
• Troglitazone

  2012cites this paper
• The Role of Podocyte Prostaglandin E2 and Angiotensin II Receptors in Glomerular Disease

  2011cites this paper
• PPAR-γ Agonists and Their Role in Type 2 Diabetes Mellitus Management

  2010cites this paper
• DIFFERENT APPROACHES FOR TREATMENT OF TYPE 2 DIABETES MELLITUS WITH SPECIAL REFERENCE TO TRADITIONAL MEDICINES: A REVIEW

  2010cites this paper
• Safety and efficacy of rosiglitazone in the elderly diabetic patient

  2009cites this paper
• Down-regulation of lipoprotein lipase increases glucose uptake in L6 muscle cells.

  2009cites this paper
• The Podocyte in Diabetic Kidney Disease

  2009cites this paper
• Scientific Review Oral Antihyperglycemic Therapy for Type 2 Diabetes

  2009cites this paper
• VHRM-4053-Safety and efficacy of rosiglitazone in the elderly

  2009cites this paper
• Peroxisome Profilerator-Activated Receptors (PPARs) – The NewFrontiers in the Treatment of Cardiovascular Diseases

  2009cites this paper
• Regulation der Fettgewebsinflammation durch Liganden von Peroxisome Proliferator Activated Receptor γ

  2008cites this paper
• Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin‐sensitizing agents

  2008cites this paper
• Adipogenic Human Adenovirus Ad‐36 Induces Commitment, Differentiation, and Lipid Accumulation in Human Adipose‐Derived Stem Cells

  2008cites this paper
• Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors

  2008cites this paper
• Type 2 diabetes and oral antihyperglycemic drugs.

  2008cites this paper
• Tratamiento de enfermedades metablicas mediante la modulacin del PPAR

  2007cites this paper
• Fatty Acid Metabolism in Diabetes

  2007cites this paper
• Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.

  2007cites this paper
• A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.

  2007cites this paper
• Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.

  2007cites this paper
• Pharmacogenetics of the PPAR genes and cardiovascular disease.

  2007cites this paper
• PPAR-γ Ligands and Diabetic Nephropathy

  2006cites this paper
• Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis.

  2006cites this paper
• PPARγ, 10 years later

  2005cites this paper
• The Cardioprotective Effects of Preconditioning with Endotoxin, but Not Ischemia, Are Abolished by a Peroxisome Proliferator-Activated Receptor-γ Antagonist

  2005cites this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cites this paper
• Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.

  2005cites this paper
• PTP1B inhibitors from Ardisia japonica

  2005cites this paper
• Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes.

  2005cites this paper
• PPAR gamma, 10 years later.

  2005cites this paper
• Advances in diabetes for the millennium: drug therapy of type 2 diabetes.

  2004cites this paper
• Comparative Effects of Available Thiazolidinediones: A Review of the Literature

  2004cites this paper
• Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines.

  2004cites this paper
• Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension

  2004cites this paper
• Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study.

  2004cites this paper
• Dyslipidemia in Type 2 Diabetes and the Effects of Thiazolidinediones

  2003cites this paper
• Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.

  2003cites this paper
• A “futile cycle” induced by thiazolidinediones in human adipose tissue?

  2003cites this paper
• Weight Effect of Current and Experimental Drugs for Diabetes Mellitus

  2003cites this paper
• Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes.

  2003cites this paper
• Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

  2003cites this paper
• The independent effects of purified EPA and DHA supplementation on cardiovascular risk in treated-hypertensive type 2 diabetic individuals

  2003cites this paper
• Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.

  2003cites this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cites this paper
• Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children

  2003cites this paper
• Therapeutic efficacy and factors that affect response of rosiglitazone in insulin-resistant type 2 diabetes

  2003cites this paper
• Analysis of the Relationship Between the Pro 12 Ala Variant in the PPAR-2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes

  2003cites this paper
• Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.

  2003cites this paper
• Insulin-lowering agents in the management of polycystic ovary syndrome.

  2003cites this paper
• The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease.

  2003cites this paper
• Muscle-specific Pparg deletion causes insulin resistance

  2003cites this paper
• Rosiglitazone inhibits the insulin‐mediated increase in PAI‐1 secretion in human abdominal subcutaneous adipocytes

  2003cites this paper
• Reply to “A “futile cycle” induced by thiazolidinediones in human adipose tissue?”

  2003cites this paper
• Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-γ2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes

  2003cites this paper
• Diabetes Therapeutics News

  2003cites this paper
• Insulin Resistance Syndrome in Children

  2003cites this paper
• Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.

  2003cites this paper
• Insulin, glucagon, and hypoglycemic drugs

  2003cites this paper
• Tiazolidinedionas. Beneficios y riesgos reales

  2002cites this paper
• Effect of thiazolidinediones on high-density lipoprotein subfractions.

  2002cites this paper
• Thiazolidinediones: A Review of Their Benefits and Risks

  2002cites this paper
• Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.

  2002cites this paper
• Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

  2002cites this paper
• Synergistic effects of troglitazone and oleate on the translatability of preproinsulin mRNA from INS-1 cells.

  2002cites this paper
• Natural PTP1B inhibitors from Broussonetia papyrifera.

  2002cites this paper
• Effects on Lipid Metabolism of Metformin and Troglitazone in Patients with Type 2 Diabetes Mellitus

  2002cites this paper
• Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.

  2002cites this paper
• Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.

  2002cites this paper
• Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats.

  2002cites this paper
• New trends in the development of oral antidiabetic drugs.

  2002cites this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cites this paper
• Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.

  2002cites this paper
• Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent.

  2002cites this paper